SMT202000084T1 - Modulatori benzoimidazol-2-il pirimidinici del recettore h4 dell'istamina - Google Patents

Modulatori benzoimidazol-2-il pirimidinici del recettore h4 dell'istamina

Info

Publication number: SMT202000084T1
Authority: SM; San Marino
Prior art keywords: benzoimidazol; histamine; receptor; modulators; pyrimidine
Prior art date: 2013-03-06

Application number

SM20200084T

Other languages

English (en)

Inventor

Magali B Hickey

Susanne Lochner

Stefan Horns

Matteo Conza

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-03-06

Filing date

2014-03-06

Publication date

2020-03-13

2014-03-06 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

2020-03-13 Publication of SMT202000084T1 publication Critical patent/SMT202000084T1/it

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/42—Separation; Purification; Stabilisation; Use of additives
- C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
- C30B29/54—Organic compounds
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
- C30B7/08—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions by cooling of the solution
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Hematology (AREA)
Immunology (AREA)
Endocrinology (AREA)
Physical Education & Sports Medicine (AREA)
Crystallography & Structural Chemistry (AREA)
Orthopedic Medicine & Surgery (AREA)
Virology (AREA)
Neurology (AREA)
Dermatology (AREA)
Metallurgy (AREA)
Materials Engineering (AREA)
Communicable Diseases (AREA)
Obesity (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Ophthalmology & Optometry (AREA)
Tropical Medicine & Parasitology (AREA)
Rheumatology (AREA)
Oncology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Emergency Medicine (AREA)
Pain & Pain Management (AREA)
Otolaryngology (AREA)

SM20200084T 2013-03-06 2014-03-06 Modulatori benzoimidazol-2-il pirimidinici del recettore h4 dell'istamina SMT202000084T1 (it)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US201361773706P	2013-03-06	2013-03-06
US201361776260P	2013-03-11	2013-03-11
US201361784909P	2013-03-14	2013-03-14
PCT/US2014/021130 WO2014138368A1 (en)	2013-03-06	2014-03-06	Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor
EP14760540.6A EP2964229B1 (en)	2013-03-06	2014-03-06	Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor

Publications (1)

Publication Number	Publication Date
SMT202000084T1 true SMT202000084T1 (it)	2020-03-13

Family

ID=51488591

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SM20200084T SMT202000084T1 (it)	2013-03-06	2014-03-06	Modulatori benzoimidazol-2-il pirimidinici del recettore h4 dell'istamina

Country Status (38)

Country	Link
US (4)	US8859575B2 (it)
EP (2)	EP2964229B1 (it)
JP (1)	JP6471103B2 (it)
KR (1)	KR102230383B1 (it)
CN (1)	CN105025898B (it)
AU (1)	AU2014225675B2 (it)
BR (1)	BR112015021463A8 (it)
CA (1)	CA2903737C (it)
CL (1)	CL2015002434A1 (it)
CR (1)	CR20150435A (it)
CY (1)	CY1122545T1 (it)
DK (1)	DK2964229T3 (it)
DO (1)	DOP2016000027A (it)
EA (1)	EA201591648A1 (it)
ES (1)	ES2773543T3 (it)
GT (1)	GT201500243A (it)
HR (1)	HRP20200253T1 (it)
HU (1)	HUE047681T2 (it)
IL (1)	IL240247B (it)
JO (1)	JO3516B1 (it)
LT (1)	LT2964229T (it)
MX (1)	MX373874B (it)
MY (1)	MY180726A (it)
NZ (1)	NZ710640A (it)
PE (1)	PE20151536A1 (it)
PH (1)	PH12015501731A1 (it)
PL (1)	PL2964229T3 (it)
PT (1)	PT2964229T (it)
RS (1)	RS59909B1 (it)
SA (1)	SA515360981B1 (it)
SG (1)	SG11201507117XA (it)
SI (1)	SI2964229T1 (it)
SM (1)	SMT202000084T1 (it)
TW (1)	TWI617554B (it)
UA (1)	UA118754C2 (it)
UY (1)	UY35370A (it)
WO (1)	WO2014138368A1 (it)
ZA (1)	ZA201507351B (it)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP5066175B2 (ja)	2006-03-31	2012-11-07	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	ヒスタミンｈ４受容体のモジュレーターとしてのベンゾイミダゾール−２−イルピリミジンおよびピラジン
US9371311B2 (en)	2008-06-30	2016-06-21	Janssen Pharmaceutica Nv	Benzoimidazol-2-yl pyrimidine derivatives
EA201591648A1 (ru)	2013-03-06	2016-02-29	Янссен Фармацевтика Нв	Бензимидазол-2-ил-пиримидиновые модуляторы рецептора гистамина h4
TWI599567B (zh)	2013-03-14	2017-09-21	健生藥品公司	Ｐ２ｘ７調節劑
TWI627174B (zh)	2013-03-14	2018-06-21	比利時商健生藥品公司	Ｐ２ｘ７調控劑
ES2689526T3 (es)	2013-03-14	2018-11-14	Janssen Pharmaceutica Nv	Moduladores de P2X7
JP6294953B2 (ja)	2013-03-14	2018-03-14	ヤンセンファーマシューティカエヌ．ベー．	Ｐ２ｘ７調節物質
EP3191492B1 (en)	2014-09-12	2019-01-09	Janssen Pharmaceutica NV	P2x7 modulators
WO2016039983A1 (en)	2014-09-12	2016-03-17	Janssen Pharmaceutica Nv	P2x7 modulating n-acyl-triazolopyrazines
JP6827113B2 (ja)	2017-01-21	2021-02-10	広州白雲山漢方現代薬業有限公司ＧｕａｎｇｚｈｏｕＨａｎｆａｎｇＰｈａｒｍａｃｅｕｔｉｃａｌＣｏ．，Ｌｔｄ．	シェーグレン症候群の治療におけるペオニフロリン−６’−ｏ−ベンゼンスルホン酸の使用
CA3111309A1 (en)	2018-09-28	2020-04-02	Janssen Pharmaceutica Nv	Monoacylglycerol lipase modulators
CN113164459B (zh)	2018-09-28	2024-09-03	詹森药业有限公司	单酰基甘油脂肪酶调节剂
CA3156100A1 (en)	2019-09-30	2021-04-08	Janssen Pharmaceutica Nv	Radiolabelled mgl pet ligands
CA3176946A1 (en)	2020-03-26	2021-09-30	Janssen Pharmaceutica Nv	Monoacylglycerol lipase modulators

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3005852A (en)	1959-12-22	1961-10-24	Gen Aniline & Film Corp	Production of sulfoxides and sulfones
GB1062357A (en)	1965-03-23	1967-03-22	Pfizer & Co C	Quinazolone derivatives
US3931195A (en)	1971-03-03	1976-01-06	Mead Johnson & Company	Substituted piperidines
US4191828A (en)	1976-04-14	1980-03-04	Richardson-Merrell Inc.	Process for preparing 2-(2,2-dicyclohexylethyl)piperidine
US4337341A (en)	1976-11-02	1982-06-29	Eli Lilly And Company	4a-Aryl-octahydro-1H-2-pyrindines
US4190601A (en)	1978-05-31	1980-02-26	Union Carbide Corporation	Production of tertiary amines by reductive alkylation
JPS6130576A (ja)	1984-07-24	1986-02-12	Ube Ind Ltd	２−アミノ−５−シアノピリミジンの製法
GB9410031D0 (en)	1994-05-19	1994-07-06	Merck Sharp & Dohme	Therapeutic agents
GB9422391D0 (en)	1994-11-05	1995-01-04	Solvay Interox Ltd	Oxidation of organosulphur compounds
AU4467396A (en)	1994-12-12	1996-07-10	Omeros Medical Systems, Inc.	Irrigation solution and method for inhibition of pain, inflammation and spasm
CA2250936A1 (en)	1996-04-03	1997-10-09	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
US5880140A (en)	1996-04-03	1999-03-09	Merck & Co., Inc.	Biheteroaryl inhibitors of farnesyl-protein transferase
WO1997036890A1 (en)	1996-04-03	1997-10-09	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
US5883105A (en)	1996-04-03	1999-03-16	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
US5939439A (en)	1996-12-30	1999-08-17	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
WO1998031369A1 (fr)	1997-01-16	1998-07-23	Sekisui Chemical Co., Ltd.	Preparations a usage externe a absorption percutanee
AU729869B2 (en)	1997-01-17	2001-02-15	Merck & Co., Inc.	Integrin antagonists
US5945422A (en)	1997-02-05	1999-08-31	Warner-Lambert Company	N-oxides of amino containing pyrido 2,3-D! pyrimidines
JP2001524079A (ja)	1997-04-07	2001-11-27	メルクエンドカンパニーインコーポレーテッド	ガンの治療方法
GB9801231D0 (en)	1997-06-05	1998-03-18	Merck & Co Inc	A method of treating cancer
WO1999018079A1 (en)	1997-10-06	1999-04-15	Warner-Lambert Company	Heteroaryl butyric acids and their derivatives as inhibitors of matrix metalloproteinases
CA2321153A1 (en)	1998-02-17	1999-08-19	Timothy D. Cushing	Anti-viral pyrimidine derivatives
JP4533534B2 (ja)	1998-06-19	2010-09-01	ノバルティスバクシンズアンドダイアグノスティックス，インコーポレーテッド	グリコーゲンシンターゼキナーゼ３のインヒビター
ES2195510T3 (es)	1999-03-25	2003-12-01	Synthon Bv	Derivados de imidazopiridina y procedimiento para prepararlos.
SI1194425T1 (sl)	1999-06-23	2005-12-31	Sanofi Aventis Deutschland	Substituirani benzimidazoli
TWI279402B (en)	1999-08-20	2007-04-21	Banyu Pharma Co Ltd	Spiro compounds having NPY antagonistic activities and agents containing the same
AU7738100A (en)	1999-09-30	2001-04-30	Neurogen Corporation	Certain alkylene diamine-substituted pyrazolo(1,5,-a)-1,5-pyrimidines and pyrazolo(1,5-a)-1,3,5-triazines
SK13752001A3 (sk)	1999-12-27	2002-07-02	Japan Tobacco, Inc.	Zlúčeniny s fúzovanými kruhmi a ich použitie ako liečiv
DE10006453A1 (de)	2000-02-14	2001-08-16	Bayer Ag	Piperidylcarbonsäuren als Integrinantagonisten
CN1592621A (zh) *	2000-04-24	2005-03-09	特瓦制药工业有限公司	唑吡坦半酒石酸盐
SK16372002A3 (sk) *	2000-04-24	2003-04-01	Teva Pharmaceutical Industries Ltd.	Zolpidem hemitartrát
CA2409762A1 (en)	2000-06-23	2002-01-03	Donald J.P. Pinto	Heteroaryl-phenyl substituted factor xa inhibitors
EP1305401A2 (en)	2000-06-28	2003-05-02	Thromb-X N.V.	Pluripotent embryonic stem (es) cell lines, improved methods for their production, and their use for germ line transmission and for the generation of genetically modified animals
KR100516535B1 (ko)	2000-07-21	2005-09-22	신젠타 파티서페이션즈 아게	4,6-디메톡시-2-(메틸설포닐)-1,3-피리미딘의 제조방법
CN100506801C (zh)	2000-09-06	2009-07-01	诺华疫苗和诊断公司	糖元合成酶激酶3的抑制剂
WO2002042272A2 (en)	2000-11-20	2002-05-30	Pharmacia Corporation	Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade
WO2002064096A2 (en)	2001-02-16	2002-08-22	Tularik Inc.	Methods of using pyrimidine-based antiviral agents
JP4544820B2 (ja)	2001-03-09	2010-09-15	オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド	複素環化合物
JP2004525139A (ja)	2001-03-23	2004-08-19	中外製薬株式会社	Ｆｌｔ−１リガンド、および血管形成により調節可能な疾患の治療におけるそれらの使用
JP2004525150A (ja)	2001-03-30	2004-08-19	スミスクラインビーチャムコーポレーション	治療用化合物としてのピラゾロピリジン類の使用
EP1408986B1 (en)	2001-05-08	2008-09-24	Yale University	Proteomimetic compounds and methods
AR035543A1 (es)	2001-06-26	2004-06-16	Japan Tobacco Inc	Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
DE60213841T2 (de)	2001-11-05	2007-02-15	Merck Patent Gmbh	Hydrazono-malonitrile
US20030187026A1 (en)	2001-12-13	2003-10-02	Qun Li	Kinase inhibitors
WO2003062235A1 (en)	2002-01-17	2003-07-31	Eli Lilly And Company	Modulators of acetylcholine receptors
TWI270542B (en)	2002-02-07	2007-01-11	Sumitomo Chemical Co	Method for preparing sulfone or sulfoxide compound
US7314937B2 (en)	2002-03-21	2008-01-01	Eli Lilly And Company	Non-imidazole aryl alkylamines compounds as histamine H3 receptor antagonists, preparation and therapeutic uses
EP1539151B1 (en)	2002-08-02	2009-03-18	Genesoft Pharmaceuticals, Inc.	Biaryl compounds having anti-infective activity
US20040127395A1 (en)	2002-09-06	2004-07-01	Desai Pragnya J.	Use of histamine H4 receptor modulators for the treatment of allergy and asthma
EP1551406A1 (en)	2002-09-06	2005-07-13	Janssen Pharmaceutica N.V.	Use of indolyl derivatives for the manufacture of a medicament for the treatment of allergic rhinitis
UA79309C2 (en)	2002-09-06	2007-06-11	Janssen Pharmaceutica Nv	Heterocyclic compounds
AU2003272285A1 (en)	2002-09-06	2004-03-29	Janssen Pharmaceutica, N.V.	Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands
WO2004029204A2 (en)	2002-09-27	2004-04-08	Merck & Co., Inc.	Substituted pyrimidines
TW200501960A (en)	2002-10-02	2005-01-16	Bristol Myers Squibb Co	Synergistic kits and compositions for treating cancer
US20040105856A1 (en)	2002-12-02	2004-06-03	Robin Thurmond	Use of histamine H4 receptor antagonist for the treatment of inflammatory responses
CN100372851C (zh)	2003-05-05	2008-03-05	弗·哈夫曼-拉罗切有限公司	具有crf活性的稠合的嘧啶衍生物
WO2004110350A2 (en)	2003-05-14	2004-12-23	Torreypines Therapeutics, Inc.	Compouds and uses thereof in modulating amyloid beta
SE0302116D0 (sv)	2003-07-21	2003-07-21	Astrazeneca Ab	Novel compounds
KR20060056377A (ko)	2003-08-13	2006-05-24	카이론 코포레이션	Ｇｓｋ-3 억제제 및 그것의 사용
MY142589A (en)	2003-09-22	2010-12-15	S Bio Pte Ltd	Benzimidazole derivatives : preparation and pharmaceutical applications
TW200526637A (en)	2003-09-30	2005-08-16	Janssen Pharmaceutica Nv	Benzoimidazole compounds
EP1670774A1 (en)	2003-09-30	2006-06-21	Janssen Pharmaceutica N.V.	Quinoxaline compounds
WO2005032490A2 (en)	2003-10-08	2005-04-14	Bristol-Myers Squibb Company	Cyclic diamines and derivatives as factor xa inhibitors
US20070099938A1 (en)	2003-10-24	2007-05-03	Ono Pharmaceutical Co., Ltd.	Antistress drug and medical use thereof
US8277831B2 (en)	2004-02-17	2012-10-02	Advanced Technologies And Regenerative Medicine, Llc.	Drug-enhanced adhesion prevention
BRPI0509164A (pt)	2004-03-25	2007-09-11	Janssen Pharmaceutica Nv	compostos de imidazol
EP1757594A4 (en)	2004-05-31	2007-12-12	Banyu Pharma Co Ltd	quinazoline derivative
DE602005027739D1 (de)	2004-06-30	2011-06-09	Janssen Pharmaceutica Nv	Arylsubstituiertes benzimidazol- und imidazopyridinether als wirkstoffe gegen krebs
CA2577947A1 (en)	2004-08-31	2006-03-09	Banyu Pharmaceutical Co., Ltd.	Novel substituted imidazole derivative
WO2006042102A2 (en)	2004-10-05	2006-04-20	Neurogen Corporation	Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds
US7381732B2 (en)	2004-10-26	2008-06-03	Bristol-Myers Squibb Company	Pyrazolobenzamides and derivatives as factor Xa inhibitors
US7442716B2 (en)	2004-12-17	2008-10-28	Merck Frosst Canada Ltd.	2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors
AU2005316091B2 (en)	2004-12-17	2011-12-01	Merck Canada Inc.	2-(phenyl or heterocyclic)-1H-phenantrho[9,10-D]imidazoles as mPGES-1 inhibitors
EP1863756A1 (en)	2005-03-24	2007-12-12	Janssen Pharmaceutica N.V.	Biaryl derived amide modulators of vanilloid vr1 receptor
WO2007044085A2 (en)	2005-05-19	2007-04-19	Xenon Pharmaceuticals Inc.	Heteroaryl compounds and their uses as therapeutic agents
EP1890703B1 (en)	2005-06-14	2016-05-11	Taigen Biotechnology	Pyrimidine compounds as chemokine receptors inhibitors
US8193206B2 (en)	2005-06-14	2012-06-05	Taigen Biotechnology Co., Ltd.	Pyrimidine compounds
BRPI0613564A2 (pt)	2005-07-04	2011-01-18	Novo Nordisk As	compostos, seus usos na preparação de composições farmacêuticas e composições farmacêuticas compreendendo os mesmos
TW200800956A (en)	2005-09-13	2008-01-01	Palau Pharma Sa	2-Aminopyrimidine derivatives
AR056560A1 (es)	2005-10-06	2007-10-10	Astrazeneca Ab	Pirrolopiridinonas como moduladores cb1
CA2627722A1 (en)	2005-10-31	2007-06-21	Merck & Co., Inc.	Cetp inhibitors
EP1956009A1 (en)	2005-12-02	2008-08-13	Mitsubishi Tanabe Pharma Corporation	Aromatic compound
JP2009527508A (ja)	2006-02-24	2009-07-30	メルクフロストカナダリミテツド	２−（フェニル又は複素環）−１ｈ−フェナントロ［９，１０−ｄ］イミダゾール
JP2009532367A (ja)	2006-03-31	2009-09-10	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	ヒスタミンｈ４受容体のモジュレーターとしてのベンゾイミダゾール−２−イルピリジン
JP5066175B2 (ja) *	2006-03-31	2012-11-07	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	ヒスタミンｈ４受容体のモジュレーターとしてのベンゾイミダゾール−２−イルピリミジンおよびピラジン
US7544698B2 (en)	2006-04-07	2009-06-09	Janssen Pharmaceutica, N.V.	Indoles and benzoimidazoles as modulators of the histamine H4 receptor
US20090069343A1 (en)	2006-04-10	2009-03-12	Dunford Paul J	Combination Histamine H1R and H4R Antagonist Therapy for Treating Pruritus
EP2019675A4 (en)	2006-05-02	2011-03-02	Merck Frosst Canada Ltd	METHOD FOR THE TREATMENT OR PREVENTION OF NEOPLASIA
CA2652238A1 (en)	2006-05-18	2007-11-29	Merck Frosst Canada Ltd.	Phenanthrene derivatives as mpges-1 inhibitors
KR20090028819A (ko)	2006-07-11	2009-03-19	얀센 파마슈티카 엔.브이.	히스타민 ｈ４ 수용체의 벤조푸로- 및 벤조티에노피리미딘 조절제
US8779154B2 (en) *	2006-09-26	2014-07-15	Qinglin Che	Fused ring compounds for inflammation and immune-related uses
CL2008000467A1 (es)	2007-02-14	2008-08-22	Janssen Pharmaceutica Nv	Compuestos derivados de 2-aminopirimidina, moduladores del receptor histamina h4; su procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno inflamatorio seleccionado de alegia, asma
PE20091035A1 (es)	2007-11-30	2009-07-16	Palau Pharma Sa	Derivados de 2-aminopirimidina
WO2009079001A1 (en)	2007-12-18	2009-06-25	Janssen Pharmaceutica N.V.	Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine h4 receptor
KR101600278B1 (ko)	2008-06-12	2016-03-08	얀센 파마슈티카 엔.브이.	히스타민 ｈ4 수용체의 다이아미노-피리딘, 피리미딘, 및 피리다진 조절제
NZ603072A (en)	2008-06-12	2013-01-25	Janssen Pharmaceutica Nv	Use of histamine H4 antagonist for the treatment of post-operative tissue adhesions after surgical procedures
TW201433568A (zh)	2008-06-30	2014-09-01	Janssen Pharmaceutica Nv	製備經取代之嘧啶衍生物的方法
KR20110022721A (ko)	2008-06-30	2011-03-07	얀센 파마슈티카 엔.브이.	벤조이미다졸-2-일 피리미딘 유도체의 제조 방법
US8852569B2 (en)	2008-08-28	2014-10-07	The General Hospital Corporation	Prevention and treatment of itch with cysteine protease inhibition
IT1395963B1 (it) *	2009-06-04	2012-11-02	Rottapharm Spa	Forme cristalline di 6-(1h-imidazol-1-il)-2-fenil chinazolina e dei suoi sali
TWI519533B (zh)	2010-11-01	2016-02-01	Ｌｇ生命科學有限公司	１－｛（２Ｓ）－２－胺基－４－［２，４－雙（三氟甲基）－５，８－二氫吡啶并［３，４－ｄ］嘧啶－７（６Ｈ）－基］－４－側氧丁基｝－５，５－二氟哌啶－２－酮酒石酸鹽之水合物
EP2465498A1 (en)	2010-11-23	2012-06-20	Faes Farma, S.A.	Diphenyl-amine derivatives: uses, process of synthesis and pharmaceutical compositions
EA201591648A1 (ru)	2013-03-06	2016-02-29	Янссен Фармацевтика Нв	Бензимидазол-2-ил-пиримидиновые модуляторы рецептора гистамина h4

2014
- 2014-03-06 EA EA201591648A patent/EA201591648A1/ru unknown
- 2014-03-06 BR BR112015021463A patent/BR112015021463A8/pt not_active Application Discontinuation
- 2014-03-06 MY MYPI2015702907A patent/MY180726A/en unknown
- 2014-03-06 LT LTEP14760540.6T patent/LT2964229T/lt unknown
- 2014-03-06 HU HUE14760540A patent/HUE047681T2/hu unknown
- 2014-03-06 HR HRP20200253TT patent/HRP20200253T1/hr unknown
- 2014-03-06 DK DK14760540.6T patent/DK2964229T3/da active
- 2014-03-06 SM SM20200084T patent/SMT202000084T1/it unknown
- 2014-03-06 CA CA2903737A patent/CA2903737C/en active Active
- 2014-03-06 EP EP14760540.6A patent/EP2964229B1/en active Active
- 2014-03-06 AU AU2014225675A patent/AU2014225675B2/en not_active Ceased
- 2014-03-06 SG SG11201507117XA patent/SG11201507117XA/en unknown
- 2014-03-06 MX MX2015011688A patent/MX373874B/es active IP Right Grant
- 2014-03-06 UY UY0001035370A patent/UY35370A/es unknown
- 2014-03-06 JP JP2015561646A patent/JP6471103B2/ja not_active Expired - Fee Related
- 2014-03-06 TW TW103107723A patent/TWI617554B/zh not_active IP Right Cessation
- 2014-03-06 CN CN201480012369.2A patent/CN105025898B/zh not_active Expired - Fee Related
- 2014-03-06 SI SI201431440T patent/SI2964229T1/sl unknown
- 2014-03-06 ES ES14760540T patent/ES2773543T3/es active Active
- 2014-03-06 KR KR1020157026804A patent/KR102230383B1/ko not_active Expired - Fee Related
- 2014-03-06 PL PL14760540T patent/PL2964229T3/pl unknown
- 2014-03-06 PE PE2015001832A patent/PE20151536A1/es not_active Application Discontinuation
- 2014-03-06 WO PCT/US2014/021130 patent/WO2014138368A1/en not_active Ceased
- 2014-03-06 JO JOP/2014/0074A patent/JO3516B1/ar active
- 2014-03-06 PT PT147605406T patent/PT2964229T/pt unknown
- 2014-03-06 US US14/199,634 patent/US8859575B2/en active Active
- 2014-03-06 EP EP19213615.8A patent/EP3660011A1/en not_active Withdrawn
- 2014-03-06 RS RS20200160A patent/RS59909B1/sr unknown
- 2014-03-06 NZ NZ710640A patent/NZ710640A/en not_active IP Right Cessation
- 2014-06-03 UA UAA201509634A patent/UA118754C2/uk unknown
- 2014-08-21 US US14/465,677 patent/US9278952B2/en not_active Expired - Fee Related
2015
- 2015-07-30 IL IL240247A patent/IL240247B/en active IP Right Grant
- 2015-08-06 PH PH12015501731A patent/PH12015501731A1/en unknown
- 2015-08-24 CR CR20150435A patent/CR20150435A/es unknown
- 2015-08-31 CL CL2015002434A patent/CL2015002434A1/es unknown
- 2015-09-02 GT GT201500243A patent/GT201500243A/es unknown
- 2015-09-03 SA SA515360981A patent/SA515360981B1/ar unknown
- 2015-10-05 ZA ZA2015/07351A patent/ZA201507351B/en unknown
2016
- 2016-01-22 DO DO2016000027A patent/DOP2016000027A/es unknown
- 2016-02-18 US US15/047,359 patent/US9434715B2/en not_active Expired - Fee Related
- 2016-08-03 US US15/227,878 patent/US9663497B2/en not_active Expired - Fee Related
2020
- 2020-02-03 CY CY20201100085T patent/CY1122545T1/el unknown

Also Published As

Publication number	Publication date
JP2016510752A (ja)	2016-04-11
TWI617554B (zh)	2018-03-11
PL2964229T3 (pl)	2020-05-18
DK2964229T3 (da)	2020-01-27
AU2014225675A1 (en)	2015-08-13
AU2014225675B2 (en)	2018-10-04
US9278952B2 (en)	2016-03-08
BR112015021463A2 (pt)	2017-07-18
EP2964229A1 (en)	2016-01-13
SG11201507117XA (en)	2015-10-29
GT201500243A (es)	2015-11-18
ES2773543T3 (es)	2020-07-13
CL2015002434A1 (es)	2016-02-05
UA118754C2 (uk)	2019-03-11
US20160159775A1 (en)	2016-06-09
HK1218513A1 (en)	2017-02-24
IL240247B (en)	2019-06-30
EP2964229A4 (en)	2016-11-16
MX2015011688A (es)	2015-12-07
SI2964229T1 (sl)	2020-02-28
KR102230383B1 (ko)	2021-03-23
JP6471103B2 (ja)	2019-02-13
CA2903737A1 (en)	2014-09-12
HUE047681T2 (hu)	2020-05-28
CR20150435A (es)	2015-11-02
KR20150126881A (ko)	2015-11-13
EP3660011A1 (en)	2020-06-03
IL240247A0 (en)	2015-09-24
JO3516B1 (ar)	2020-07-05
US20140364607A1 (en)	2014-12-11
PE20151536A1 (es)	2015-10-28
TW201516042A (zh)	2015-05-01
SA515360981B1 (ar)	2016-06-23
NZ710640A (en)	2019-03-29
US8859575B2 (en)	2014-10-14
RS59909B1 (sr)	2020-03-31
LT2964229T (lt)	2020-02-10
BR112015021463A8 (pt)	2019-11-19
ZA201507351B (en)	2017-08-30
US9663497B2 (en)	2017-05-30
EP2964229B1 (en)	2019-12-11
US20140256942A1 (en)	2014-09-11
MY180726A (en)	2020-12-08
UY35370A (es)	2014-09-30
DOP2016000027A (es)	2017-04-30
PT2964229T (pt)	2020-03-23
PH12015501731B1 (en)	2015-10-19
CN105025898B (zh)	2018-01-23
US9434715B2 (en)	2016-09-06
CN105025898A (zh)	2015-11-04
MX373874B (es)	2020-03-26
PH12015501731A1 (en)	2015-10-19
CA2903737C (en)	2021-05-18
CY1122545T1 (el)	2021-01-27
WO2014138368A1 (en)	2014-09-12
EA201591648A1 (ru)	2016-02-29
US20160340337A1 (en)	2016-11-24
HRP20200253T1 (hr)	2020-05-29

Publication	Publication Date	Title
ZA201507351B (en)	2017-08-30	Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor
PL3024827T3 (pl)	2020-10-19	Podstawione pochodne chinazolin-4-onu
GB201303109D0 (en)	2013-04-10	Novel pyrimidine compounds
IL240363A0 (en)	2015-09-24	נגזרות פירידין כמעכבי rock עדינים
EP3030233A4 (en)	2017-01-18	Oxazole orexin receptor antagonists
EP2970968A4 (en)	2016-09-07	BICYCLIC NUCLEOSIDES BRIDGED
PL2874772T3 (pl)	2016-11-30	Kompensacyjny uchwyt zaciskowy
SG11201601609RA (en)	2016-04-28	Glass substrate
EP3063083A4 (en)	2017-06-21	Altitude-sensitive destination entry
EP3072318A4 (en)	2016-11-23	PROFILE INTEGRATION MANAGEMENT
SG10201706775RA (en)	2017-09-28	Optoelectronic component
EP2986719A4 (en)	2016-10-26	FUSION POLYMERASES
EP2992165B8 (en)	2020-03-04	Merlin drilling riser assembly
EP3067480A4 (en)	2017-06-07	Joint structure
IL242782A0 (en)	2016-02-01	cxcr7 receptor modulators
LT2989248T (lt)	2019-02-25	Dekstrino pagrindo dengiamieji sluoksniai
SG11201507500XA (en)	2015-10-29	Inorganic fiber
EP2948625A4 (en)	2016-08-24	OPTICAL DRILLING MEASUREMENT
EP2976864A4 (en)	2016-11-09	RECOMMENDATIONS OF APPLICATION
EP3063664A4 (en)	2017-07-05	Topic-wise collaboration integration
GB2510931B (en)	2015-01-21	Chod rig
EP3005147A4 (en)	2017-01-11	Using aliases for date entry
GB201300061D0 (en)	2013-02-20	Angular adjustment rig
GB201306013D0 (en)	2013-05-15	compensation
GB201318284D0 (en)	2013-11-27	Construction of surfaces